Regeneron’s Eylea Win Leaves an Elephant in the Room

Published by
The Street

By Maxx Chatsko Regeneron’s Eylea eye-disorder drug faces competitive pressure on multiple fronts. New data could cement its dominance. The World’s largest drug developers typically generate revenue from a portfolio of approved drugs, but some have grown dangerously dependent on a single product. AbbVie (ABBV) – Get AbbVie Inc. Report leaned on Humira sales in the U.S. for 31% of total global revenue in 2021. That presents a problem when the drug loses patent exclusivity in summer 2023. Indeed, more than 10 different biosimilars could be vying for market share 12 months from now. To be fair, H…

Read More

See also  Despite coronavirus, millions of workers can't stay home. Are they safe?

Leave a Reply